Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of QHRD106 in Healthy Subjects
NCT06380699Phase 1Completed
- Sponsor
- Changzhou Qianhong Biopharma Co., Ltd.
- Start
- Mar 2023
- Primary completion
- Nov 2023
- Modality
- Recombinant Proteins and Enzymes, PEGylated Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of QHRD106 in acute ischemic stroke (AIS) (5 arms), sponsored by Changzhou Qianhong Biopharma Co., Ltd. Primary endpoints: Incidence, severity, and causality of adverse events, Plasma measurements of QHRD106 and 1 more. Started Mar 2023; status: completed.
02
Drugs
QHRD106
03
Conditions
acute ischemic stroke (AIS)
Beyond the preview
Go deeper on NCT06380699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06380699.